Flow cytometric analyses of CD4+CD28− T cells confirmed the expected immunophenotype in BM from healthy donors and patients with different hematological cancers, suggesting a robust and efficient prospective isolation of this rare cell type (Fig. 5d and Extended Data Fig. 8e). Here, CD28 is linked to hematopoietic and lymphoid cell neoplasm.